Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria…

Posted: April 3, 2025 at 2:45 am

Ad hoc announcement pursuant to Art. 53 LR

Continued here:
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria...

Related Posts